J&J outlines goals through 2019

Johnson & Johnson (NYSE:JNJ) plans to submit 15 regulatory applications for NMEs by the end of this decade, including more than 10 for candidates with the potential to exceed $1 billion in revenue. The company also expects to seek more than 40 line extensions. J&J announced the goals during a pharmaceutical business review on Wednesday.

Among the 15, J&J outlined four programs to treat cancer, four in infectious disease, two in immunology and five in CNS. The company did not say which of these programs could reach the $1 billion goal. ...